Skip to main content
SpringerLink
Log in

Gut Microbiome and Hepatic Steatosis (Steatotic Liver Disease)

  • Reference work entry
  • First Online:
Gut Microbiome, Microbial Metabolites and Cardiometabolic Risk

Part of the book series: Endocrinology ((ENDOCR))

  • 232 Accesses

Abstract

The gut–liver axis represents complex pathways of communication between the gut, the gut microbiota, and the liver that influence hepatic and systemic health. Hepatic steatosis, characterized by an accumulation of lipids in liver tissue, is one of the leading causes of chronic liver disease worldwide, with the potential to progress to more serious and irreversible forms of hepatic disease. It is becoming apparent that interactions between the host and its gut microbiota contribute to hepatic steatosis, but determining whether these interactions initiate hepatic steatosis and/or drive disease progression is difficult. What is clear is that metabolites produced by the gut microbiota influence aspects of hepatic steatosis, and they may prove invaluable in non-invasive diagnostic tools to allow earlier detection of fatty liver disease, reducing the global burden of disease and improving patient outcomes. This chapter summarizes our current knowledge on the role of the gut–liver axis in hepatic steatosis and provides information on microbiota-targeted interventions that may be able to ameliorate or treat hepatic steatosis in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 449.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Al-Waiz M, Ayesh R, Mitchell SC, Idle JR, Smith RL. Disclosure of the metabolic retroversion of trimethylamine N-oxide in humans: a pharmacogenetic approach. Clin Pharmacol Ther. 1987;42(6):608–12.

    Article  CAS  PubMed  Google Scholar 

  • Brial F, Chilloux J, Nielsen T, Vieira-Silva S, Falony G, Andrikopoulos P, et al. Human and preclinical studies of the host–gut microbiome co-metabolite hippurate as a marker and mediator of metabolic health. Gut. 2021:gutjnl-2020-323314.

    Google Scholar 

  • Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol. 2015;11(10):577–91.

    Article  CAS  PubMed  Google Scholar 

  • Canfora EE, Meex RCR, Venema K, Blaak EE. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol. 2019;15(5):261–73.

    Article  CAS  PubMed  Google Scholar 

  • Caussy C, Hsu C, Lo M-T, Liu A, Bettencourt R, Ajmera VH, et al. Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology. 2018;68(3):918–32.

    Article  CAS  PubMed  Google Scholar 

  • Caussy C, Ajmera VH, Puri P, Hsu CL-S, Bassirian S, Mgdsyan M, et al. Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease. Gut. 2019;68(10):1884–92.

    Article  CAS  PubMed  Google Scholar 

  • Clarke G, Sandhu KV, Griffin BT, Dinan TG, Cryan JF, Hyland NP. Gut reactions: breaking down xenobiotic-microbiome interactions. Pharmacol Rev. 2019 Apr;71(2):198–224.

    Article  CAS  PubMed  Google Scholar 

  • Craven L, Rahman A, Nair Parvathy S, Beaton M, Silverman J, Qumosani K, et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial. Am J Gastroenterol. 2020;115(7):1055–65.

    Article  PubMed  Google Scholar 

  • Del Barrio M, Lavín L, Santos-Laso Á, Arias-Loste MT, Odriozola A, Rodriguez-Duque JC, et al. Faecal microbiota transplantation, paving the way to treat non-alcoholic fatty liver disease. Int J Mol Sci. 2023;24(7):6123.

    Article  PubMed  PubMed Central  Google Scholar 

  • Delgado TC, de las Heras J, Martínez-Chantar ML. understanding gut-liver axis nitrogen metabolism in fatty liver disease. Front Endocrinol (Lausanne). 2022;13:1058101.

    Article  PubMed  Google Scholar 

  • Delzenne NM, Bindels LB. Microbiome metabolomics reveals new drivers of human liver steatosis. Nat Med. 2018;24(7):906–7.

    Article  CAS  PubMed  Google Scholar 

  • Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature. 2019;575(7783):505–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69(4):896–904.

    Article  PubMed  Google Scholar 

  • Forlano R, Sivakumar M, Mullish BH, Manousou P. Gut microbiota – a future therapeutic target for people with non-alcoholic fatty liver disease: a systematic review. Int J Mol Sci. 2022;23(15):8307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gan L, Feng Y, Du B, Fu H, Tian Z, Xue G, et al. Bacteriophage targeting microbiota alleviates non-alcoholic fatty liver disease induced by high alcohol-producing Klebsiella pneumoniae. Nat Commun. 2023;14(1):3215.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017;14(8):491–502.

    Article  PubMed  Google Scholar 

  • Han S, Van Treuren W, Fischer CR, Merrill BD, DeFelice BC, Sanchez JM, et al. A metabolomics pipeline for the mechanistic interrogation of the gut microbiome. Nature. 2021;595(7867):415–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506–14.

    Article  PubMed  Google Scholar 

  • Horst AK, Neumann K, Diehl L, Tiegs G. Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells. Cell Mol Immunol. 2016;13(3):277–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hoyles L, Swann J. Influence of the human gut microbiome on the metabolic phenotype. In: The handbook of metabolic phenotyping. Elsevier; Netherlands, 2019. p. 535–60.

    Google Scholar 

  • Hoyles L, Fernández-Real J-M, Federici M, Serino M, Abbott J, Charpentier J, et al. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat Med. 2018a;24(7):1070–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hoyles L, Jiménez-Pranteda ML, Chilloux J, Brial F, Myridakis A, Aranias T, et al. Metabolic retroconversion of trimethylamine N-oxide and the gut microbiota. Microbiome. 2018b;6(1):73.

    Article  PubMed  PubMed Central  Google Scholar 

  • Hsu CL, Schnabl B. The gut-liver axis and gut microbiota in health and liver disease. Nat Rev Microbiol. 2023;21:719–33.

    Article  CAS  PubMed  Google Scholar 

  • Hughes R, Magee EA, Bingham S. Protein degradation in the large intestine: relevance to colorectal cancer. Curr Issues Intest Microbiol. 2000;1(2):51–8.

    CAS  PubMed  Google Scholar 

  • Joyce SA, Gahan CGM. Bile acid modifications at the microbe-host interface: potential for nutraceutical and pharmaceutical interventions in host health. Annu Rev Food Sci Technol. 2016;7:313–33.

    Article  CAS  PubMed  Google Scholar 

  • Kaufmann B, Seyfried N, Hartmann D, Hartmann P. Probiotics, prebiotics, and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease. Am J Physiol Gastrointest Liver Physiol. 2023;325(1):G42–61.

    Article  CAS  PubMed  Google Scholar 

  • Khan MT, Dwibedi C, Sundh D, Pradhan M, Kraft JD, Caesar R, et al. Synergy and oxygen adaptation for development of next-generation probiotics. Nature. 2023;620(7973):381–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kim H, Lee DS, An TH, Park H-J, Kim WK, Bae K-H, et al. Metabolic spectrum of liver failure in type 2 diabetes and obesity: From NAFLD to NASH to HCC. Int J Mol Sci. 2021;22(9):4495.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.

    Article  PubMed  Google Scholar 

  • Koh A, Molinaro A, Ståhlman M, Khan MT, Schmidt C, Mannerås-Holm L, et al. Microbially produced imidazole propionate impairs insulin signaling through mTORC1. Cell. 2018;175(4):947–961.e17.

    Article  CAS  PubMed  Google Scholar 

  • Lützhøft DO, Sinioja T, Christoffersen BØ, Jakobsen RR, Geng D, Ahmad HFB, et al. Marked gut microbiota dysbiosis and increased imidazole propionate are associated with a NASH Göttingen Minipig model. BMC Microbiol. 2022;22(1):287.

    Article  PubMed  PubMed Central  Google Scholar 

  • Mafra D, Barros AF, Fouque D. Dietary protein metabolism by gut microbiota and its consequences for chronic kidney disease patients. Future Microbiol. 2013;8(10):1317–23.

    Article  CAS  PubMed  Google Scholar 

  • Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal. Microbiome. 2015;3:31.

    Article  PubMed  PubMed Central  Google Scholar 

  • Menghini R, Hoyles L, Cardellini M, Casagrande V, Marino A, Gentileschi P, et al. ITCH E3 ubiquitin ligase downregulation compromises hepatic degradation of branched-chain amino acids. Mol Metab. 2022;59:101454.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Molinaro A, Bel Lassen P, Henricsson M, Wu H, Adriouch S, Belda E, et al. Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology. Nat Commun. 2020;11(1):5881.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pant A, Maiti TK, Mahajan D, Das B. Human gut microbiota and drug metabolism. Microb Ecol. 2023;86(1):97–111.

    Google Scholar 

  • Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–86. https://doi.org/10.1097/HEP.0000000000000520.

  • Rowan-Nash AD, Korry BJ, Mylonakis E, Belenky P. Cross-domain and viral interactions in the microbiome. Microbiol Mol Biol Rev. 2019;83(1):e00044–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Salminen S, Collado MC, Endo A, Hill C, Lebeer S, Quigley EMM, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol. 2021;18(9):649–67.

    Article  PubMed  PubMed Central  Google Scholar 

  • Sarafian MH, Lewis MR, Pechlivanis A, Ralphs S, McPhail MJW, Patel VC, et al. Bile acid profiling and quantification in biofluids using ultra-performance liquid chromatography tandem mass spectrometry. Anal Chem. 2015;87(19):9662–70.

    Article  CAS  PubMed  Google Scholar 

  • Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14(8):e1002533.

    Article  PubMed  PubMed Central  Google Scholar 

  • Sharpton SR, Ajmera V, Loomba R. Emerging role of the gut microbiome in nonalcoholic fatty liver disease: from composition to function. Clin Gastroenterol Hepatol. 2019;17(2):296–306.

    Article  CAS  PubMed  Google Scholar 

  • Shkoporov AN, Hill C. Bacteriophages of the human gut: the ‘known unknown’ of the microbiome. Cell Host Microbe. 2019;25(2):195–209.

    Article  CAS  PubMed  Google Scholar 

  • Shoaie S, Ghaffari P, Kovatcheva-Datchary P, Mardinoglu A, Sen P, Pujos-Guillot E, et al. Quantifying diet-Induced metabolic changes of the human gut microbiome. Cell Metab. 2015;22(2):320–31.

    Article  CAS  PubMed  Google Scholar 

  • Simrén M, Barbara G, Flint HJ, Spiegel BMR, Spiller RC, Vanner S, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62(1):159–76.

    Article  PubMed  Google Scholar 

  • Swanson KS, Gibson GR, Hutkins R, Reimer RA, Reid G, Verbeke K, et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nat Rev Gastroenterol Hepatol. 2020;17(11):687–701.

    Article  PubMed  PubMed Central  Google Scholar 

  • Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836–46.

    Article  CAS  PubMed  Google Scholar 

  • Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15(7):397–411.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Walker AW, Hoyles L. Human microbiome myths and misconceptions. Nat Microbiol. 2023;8(8):1392–6.

    Article  CAS  PubMed  Google Scholar 

  • Weiner ID. Roles of renal ammonia metabolism other than in acid-base homeostasis. Pediatr Nephrol. 2017;32(6):933–42.

    Article  PubMed  Google Scholar 

  • Xiao J, Ng CH, Chan KE, Fu C, Tay P, Yong JN, et al. Hepatic, extra-hepatic outcomes and causes of mortality in NAFLD – an umbrella overview of systematic review of meta-analysis. J Clin Exp Hepatol. 2023;13(4):656–65.

    Article  CAS  PubMed  Google Scholar 

  • Xue L, Deng Z, Luo W, He X, Chen Y. Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial. Front Cell Infect Microbiol. 2022;12:759306.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yuan J, Chen C, Cui J, Lu J, Yan C, Wei X, et al. Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae. Cell Metab. 2019;30(4):675–688.e7.

    Article  CAS  PubMed  Google Scholar 

  • Zhao M, Zhao L, Xiong X, He Y, Huang W, Liu Z, et al. TMAVA, a metabolite of intestinal microbes, is increased in plasma from patients with liver steatosis, inhibits γ-butyrobetaine hydroxylase, and exacerbates fatty liver in mice. Gastroenterology. 2020;158(8):2266–2281.e27.

    Article  CAS  PubMed  Google Scholar 

  • Zheng X, Xie G, Zhao A, Zhao L, Yao C, Chiu NHL, et al. The footprints of gut microbial-mammalian co-metabolism. J Proteome Res. 2011;10(12):5512–22.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nottingham Trent University, Nottingham, UK

    Lesley Hoyles

Authors
  1. Lesley Hoyles
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lesley Hoyles .

Editor information

Editors and Affiliations

  1. Department of Systems Medicine, University of Tor Vergata, Rome, Italy

    Massimo Federici

  2. Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy

    Rossella Menghini

Rights and permissions

Reprints and permissions

Copyright information

© 2024 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Hoyles, L. (2024). Gut Microbiome and Hepatic Steatosis (Steatotic Liver Disease). In: Federici, M., Menghini, R. (eds) Gut Microbiome, Microbial Metabolites and Cardiometabolic Risk. Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-031-35064-1_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-35064-1_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-35063-4

  • Online ISBN: 978-3-031-35064-1

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation